Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.53 |
| ▸ | CMA1 | P23946 | 4/20 | 0.48 |
| ▸ | XIAP | P98170 | 3/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 9/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10297435 | 1.00 | REN (0.53) | RENCMA1XIAPOPRM1OPRD1 | |
| SCHEMBL10297440 | 1.00 | REN (0.53) | RENCMA1XIAPOPRM1OPRD1 | |
| SCHEMBL14479879 | 1.00 | REN (0.53) | RENCMA1XIAPOPRM1OPRD1 | |
| SCHEMBL14479877 | 0.97 | REN (0.53) | RENCMA1XIAPOPRM1OPRD1 | |
| SCHEMBL10297451 | 0.97 | REN (0.53) | RENCMA1XIAPOPRM1OPRD1 | |
| SCHEMBL10297433 | 0.97 | REN (0.53) | RENCMA1XIAPOPRM1OPRD1 | |
| SCHEMBL10297426 | 0.87 | XIAP (0.52) | CMA1XIAPOPRM1OPRD1OPRK1 | |
| SCHEMBL10297452 | 0.87 | XIAP (0.52) | CMA1XIAPOPRM1OPRD1OPRK1 | |
| SCHEMBL10297439 | 0.86 | REN (0.44) | RENCMA1 | |
| SCHEMBL10297468 | 0.86 | REN (0.44) | RENCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211637-B2 | Proteinase K inhibitors, methods and compositions therefor | Life Technologies Corporation (US) | 2012-07-03 | — | — | US | disclosed |
| WO-2010071833-A1 | PROTEINASE K INHIBITORS, METHODS AND COMPOSITIONS THEREFOR | Life Technologies Corporation (US) | 2010-06-24 | — | — | WO | disclosed |
| US-20100159482-A1 | PROTEINASE K INHIBITORS, METHODS AND COMPOSITIONS THEREFOR | Life Technologies Corporation (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100159482-A1 | PROTEINASE K INHIBITORS, METHODS AND COMPOSITIONS THEREFOR | CPSF7, CTSL, CTSK | REN 564/4885CMA1 84/4885XIAP 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.